Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
A model of two zinc-finger nucleases bound to DNA overlaid on an image of a metaphase chromosome spread. The side chains shown are key to the dimer interface of the cleavage domains, according to Miller et al. Two papers in this issue redesign the dimer interface to reduce off-target DNA cleavage. (pp 778 and 786) Credit: Jeffrey C. Miller
Whether it's wooing investors, building a patent portfolio, critiquing multinational pharmaceutical firms or tackling hereditary diseases in her native community, Avesthagen CEO Villoo Morawala Patell brings a unique mix of dynamism and intellectual verve to the table.
As more high-ticket biologic drugs reach the marketplace, the biotech industry may be increasingly beset by counterfeiters. Do regulators and law enforcement have the tools they need?
Securing material transfer agreements can be burdensome for academics and make downstream research prohibitively expensive, particularly for small startups with limited resources. Two technology-transfer professionals debate the pros and cons of such contracts.
Instrumentation aside, algorithms for matching mass spectra to proteins are at the heart of shotgun proteomics. How do these algorithms work, what can we expect of them and why is it so difficult to find protein modifications?